3 Things to Love About GlaxoSmithKline

LONDON -- There are things to love and loathe about most companies. Today, I'm going to tell you about three things to love about FTSE 100 pharma giant GlaxoSmithKline  (LSE: GSK  ) (NYSE: GSK  ) .

I'll also be asking whether these positive factors make Glaxo a good investment today.

De-rating
If you look at a chart for Glaxo since the turn of the millennium, you'll see that the share price has gone nowhere. In fact, the shares have fallen from more than 20 pounds in 2000 to 14 pounds today. Yet, at the same time, Glaxo's business has progressed very nicely, growing revenues and profits over the period.

How can a company's share price decline when its business has actually prospered? The answer is that Glaxo's shares have "de-rated" over the past 13 years. In 2000, investors were paying an eye-watering 30 times earnings; today, you can buy the shares at a far more reasonable 13 times earnings.

Dividend
Glaxo's growing revenues and profits have enabled the company to build a strong record of annual dividend increases, as the table below shows.

*Forecast.

If Glaxo's price-to-earnings ratio is hugely more attractive today than back in 2000, so is the dividend yield: The yield at the turn of the millennium was just 2%; today, it's a juicy 5.3%.

Defensive
Despite the long-term slow decline in the share price as the stock has de-rated to a reasonable P/E, Glaxo's shares have been less volatile than the market during periods of stress.

Big pharma is a "defensive" sector, meaning it is less affected by economic conditions than "cyclical" sectors, such as house builders. Thus, in the 2007-'09 bear market, while the FTSE 100 fell 48% -- and cyclical companies considerably further -- Glaxo declined a relatively modest 20%.

A good investment?
Glaxo's shares have underperformed the FTSE 100 over the past six months -- falling 5% versus a 10% rise in the index -- as many investors have become more optimistic and backed cyclical shares for a recovery.

As I mentioned earlier, Glaxo's P/E and dividend yield are currently at historically attractive levels. If I were in the market for a sleep-well-at-night, defensive income share, the U.K.'s premier pharma company would certainly be on my list of stocks to consider.

You may be interested to know that Glaxo is a top holding of one investor with a proven track record of buying great dividend shares. Renowned City fund manager Neil Woodford has thrashed the FTSE 100 over the past five, 10 and 15 years with his 20 billion pound funds.

You can learn all about this master investor's methods -- and eight of his current favorite blue chips -- in a free and exclusive Motley Fool report. This report is available to private investors for a limited time only, but you can download it right now: simply click here.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2208045, ~/Articles/ArticleHandler.aspx, 11/23/2014 8:48:10 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement